Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Molecular Partners Ag ADR (MOLN)
Molecular Partners Ag ADR (MOLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 161,412
  • Shares Outstanding, K 36,354
  • Annual Sales, $ 198,680 K
  • Annual Income, $ 123,500 K
  • 60-Month Beta 0.83
  • Price/Sales 14.46
  • Price/Cash Flow 1.33
  • Price/Book 0.76
Trade MOLN with:

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.33 +1.62%
on 02/22/24
4.94 -10.96%
on 02/06/24
-0.20 (-4.35%)
since 01/22/24
3-Month
3.72 +18.28%
on 01/02/24
5.08 -13.39%
on 01/03/24
+0.06 (+1.38%)
since 11/17/23
52-Week
3.53 +24.65%
on 10/30/23
7.32 -39.89%
on 06/05/23
-1.95 (-30.71%)
since 02/22/23

Most Recent Stories

More News
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy

Ambrx Pharmaceuticals, Inc. could see positive earnings next year. And while share value could go down, analysts thin rate AMAM a Moderate Buy

AMAM : 27.93 (+0.83%)
MOLN : 4.40 (-0.90%)
Incyte Announces Agreement to Acquire Medicxi-backed Villaris Therapeutics and Auremolimab (VM6), an Anti-IL-15Rβ Monoclonal Antibody

Incyte (NASDAQ:INCY) today announced that the Company has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development...

INCY : 60.91 (+0.96%)
MOLN : 4.40 (-0.90%)
PCVX : 73.87 (+2.23%)
AURA : 8.73 (-0.80%)
CNTA : 10.75 (+3.37%)
Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Molecular Partners AG (MOLN) Investors of Class Action and Last Few Hours to Actively Participate

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or the “Company”) (NASDAQ:...

MOLN : 4.40 (-0.90%)
FINAL INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Molecular Partners AG with Losses of $100,000 to Contact the Firm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Molecular Partners AG (“Molecular Partners” or “the Company”)...

MOLN : 4.40 (-0.90%)
MOLECULAR PARTNERS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Molecular Partners AG and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Molecular Partners AG (“Molecular Partners” or...

MOLN : 4.40 (-0.90%)
MOLN SHAREHOLDER ALERT: Jakubowitz Law Reminds Molecular Partners Shareholders of a Lead Plaintiff Deadline of September 12, 2022

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Molecular Partners AG (NASDAQ:...

MOLN : 4.40 (-0.90%)
MOLN LAWSUIT ALERT: Levi & Korsinsky Notifies Molecular Partners AG Investors of a Class Action Lawsuit and Upcoming Deadline

/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Molecular Partners AG ("Molecular Partners" or the "Company") (NASDAQ: MOLN) of a class action...

MOLN : 4.40 (-0.90%)
MOLN DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Molecular Partners AG Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action - MOLN

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Molecular Partners AG (NASDAQ: MOLN): (i)...

MOLN : 4.40 (-0.90%)
MOLN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 12, 2022 in the Class Action Filed on Behalf of Molecular Partners AG Shareholders

/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Molecular Partners AG (NASDAQ: MOLN)...

MOLN : 4.40 (-0.90%)
MOLN SHAREHOLDER ALERT: Jakubowitz Law Reminds Molecular Partners Shareholders of a Lead Plaintiff Deadline of September 12, 2022

/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Molecular Partners AG (NASDAQ:...

MOLN : 4.40 (-0.90%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar